ProtoKinetix, Inc. (OTCPK:PKTX) insider have most recently took part in a trading activity. On Sep 2, 2016 Smith Clarence Edward, President & CEO, 10% Owner bought 1,250,000 shares having total worth of $50,000 at the price of $0.04 per share, following the transaction a total of 46,547,910 shares owned by Smith Clarence Edward. Before this latest buy, Smith Clarence Edward purchased PKTX at 1 other times during the past twelve months, for a total investment of $4,538 at an average of $0.05 per share.
The stock has experienced a total of 7 insider trades in the past three months. These trades include 7 buy trades. Furthermore, over the past 12 months , the stock was traded 14 times by insiders. an employee of the company was the buyer in 14 instances.
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
|Type||1 Mo||3 Mo||6 Mo||1 Yr||2 Yr||3 Yr|
|Average Purchase Return||44%||21%||41%||40%||-||-|
|Purchase Success Rate||12/17||5/17||2/17||1/17||-||-|
|Average Sale Return||–||–||–||–||–||–|
|Sale Success Rate||–||–||–||–||–||–|
Shares of ProtoKinetix, Inc. (OTCPK:PKTX) traded down 3.39% on Sep 8, 2016, hitting $0.06. 71,700 shares of the company’s stock traded hands. ProtoKinetix, Inc. has a 52 week low of $0.04 and a 52 week high of $0.15. The company’s market cap is $0 million.
ProtoKinetix, Incorporated, a development stage company, was incorporated under the laws of the State of Nevada on December 23, 1999. It is a medical research company whose mission is the advancement of human health care. The Company has developed a body of trade secrets and know-how relating to the development, use and manufacture of AAG(tm), including limited to the optimization of materials for efforts, and how to maximize sensitivity, speed-to-result, specificity, stability, purity and reproducibility. It owns the world-wide rights to a family of anti-aging glycoproteins, trademarked as AAGPs(tm). In scientific tests AAGPs(tm) have demonstrated the ability to enhance the health and extend the life of biologically sensitive cells which have been subjected to severe stress conditions under laboratory controlled test conditions. AAGPs(tm) are stable and non-toxic. The Company’s competitors are substantially larger and have greater financial, research, manufacturing, and marketing resources. The Company’s AAGP(tm) have commercial applications in markets and circumstances that fall under government regulations ranging from none to limited to extensive.
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018